Use of exogenous pulmonary surfactant in acute respiratory distress syndrome (ARDS): Role in SARS-CoV-2-related lung injury

Several pre-clinical and clinical trials show that exogenous pulmonary surfactant has clinical efficacy in inflammatory lung diseases, especially ARDS. By infecting type II alveolar cells, COVID-19 interferes with the production and secretion of the pulmonary surfactant and therefore causes an incre...

Descripción completa

Detalles Bibliográficos
Autores principales: Cattel, Francesco, Giordano, Susanna, Bertiond, Cecilia, Lupia, Tommaso, Corcione, Silvia, Scaldaferri, Matilde, Angelone, Lorenzo, De Rosa, Francesco Giuseppe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7916525/
https://www.ncbi.nlm.nih.gov/pubmed/33657448
http://dx.doi.org/10.1016/j.resp.2021.103645

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7916525/
https://www.ncbi.nlm.nih.gov/pubmed/33657448
http://dx.doi.org/10.1016/j.resp.2021.103645

Ejemplares similares